Results of preclinical studies with a highly potent KRAS (G12D mutant) inhibitor for the treatment of cancer were recently reported by researchers from Betta Pharmaceuticals Co. Ltd. BPI-501836 displayed higher inhibitory activity at KRAS G12D, when compared to the reference compound (IC50=0.25 and 2.4 nM, respectively) in NanoBRET assays.
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with poor prognosis and limited therapeutic options, and it accounts for 15%-20% of female invasive breast cancers.
Researchers from Beijing Pharscin Innobio Co. Ltd. presented the discovery and preclinical characterization of a novel highly selective poly (ADP-ribose) polymerase 7 (PARP7) inhibitor, HSN-002066, being developed for the treatment of cancer.
The overexpression of transferrin receptor 1 (TfR1) has been reported in several cancer types but is also expressed in normal cell types such as erythroblasts. On the other hand, epidermal growth factor receptor (EGFR) is highly expressed in epithelial carcinomas.
A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord blood-derived NK cells that were genetically modified to express CD5-directed CAR and simultaneously produce IL-15 to support NK cell survival and proliferation.
Exact Sciences Corp., Seekin Inc. and Serum Detect Inc. presented encouraging results for the field of multicancer early detection at the American Association for Cancer Research annual meeting in San Diego April 6-10, but delays in coverage may slow further progress.
Researchers from Beigene (Beijing) Co. Ltd. have disclosed preclinical data for BGB-B167, a first-in-class immunoglobulin G (IgG)-based bispecific antibody (bsAb) targeting 4-1BB and CEA, being developed for the treatment of advanced or metastatic solid tumors.
Insilico Medicine Inc. recently discussed the generative artificial intelligence (AI)-powered design of ISM-6331, a novel, potent, selective and non-covalent pan-TEAD inhibitor that blocks TEAD palmitoylation to suppress YAP/TAZ-TEAD transcriptional activity and shows strong antitumor activity in a preclinical model of Hippo pathway-dysregulated cancers and other solid cancers were discussed.
